- Home
- GCTK vs INM Comparison
GCTK vs INM Comparison
Compare GCTK & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- INM
- Stock Information
- Founded
- GCTK 2001
- INM 1981
- Country
- GCTK United States
- INM Canada
- Employees
- GCTK N/A
- INM N/A
- Industry
- GCTK Medical/Dental Instruments
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- INM Health Care
- Exchange
- GCTK Nasdaq
- INM Nasdaq
- Market Cap
- GCTK 3.7M
- INM 3.2M
- IPO Year
- GCTK N/A
- INM N/A
- Fundamental
- Price
- GCTK $6.01
- INM $2.66
- Analyst Decision
- GCTK
- INM
- Analyst Count
- GCTK 0
- INM 0
- Target Price
- GCTK N/A
- INM N/A
- AVG Volume (30 Days)
- GCTK 1.7M
- INM 5.8M
- Earning Date
- GCTK 08-12-2025
- INM 05-12-2025
- Dividend Yield
- GCTK N/A
- INM N/A
- EPS Growth
- GCTK N/A
- INM N/A
- EPS
- GCTK N/A
- INM N/A
- Revenue
- GCTK N/A
- INM $4,920,990.00
- Revenue This Year
- GCTK N/A
- INM N/A
- Revenue Next Year
- GCTK N/A
- INM N/A
- P/E Ratio
- GCTK N/A
- INM N/A
- Revenue Growth
- GCTK N/A
- INM N/A
- 52 Week Low
- GCTK $5.11
- INM $1.72
- 52 Week High
- GCTK $3,756.00
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- GCTK 42.88
- INM 45.77
- Support Level
- GCTK $5.11
- INM $2.69
- Resistance Level
- GCTK $6.05
- INM $3.28
- Average True Range (ATR)
- GCTK 0.59
- INM 0.20
- MACD
- GCTK 0.07
- INM -0.05
- Stochastic Oscillator
- GCTK 28.22
- INM 9.81
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.